| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1966* | 2021 |
| Dose-finding based on efficacy–toxicity trade-offs PF Thall, JD Cook Biometrics 60 (3), 684-693, 2004 | 556 | 2004 |
| The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised … DJ Beard, LJ Davies, JA Cook, G MacLennan, A Price, S Kent, J Hudson, ... The Lancet 394 (10200), 746-756, 2019 | 252 | 2019 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 236 | 2022 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 77 | 2022 |
| Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations PF Thall, JD Cook, EH Estey Journal of Biopharmaceutical Statistics 16 (5), 623-638, 2006 | 77 | 2006 |
| Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody GB Sivolapenko, V Douli, G Sirmalis, E Merkouri, K Konstantinides, ... The Lancet 346 (8991-8992), 1662-1666, 1995 | 65 | 1995 |
| Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias … M De Lima, RE Champlin, PF Thall, X Wang, TG Martin, JD Cook, ... Leukemia 22 (2), 258-264, 2008 | 59 | 2008 |
| Bayesian design of single-arm phase II clinical trials with continuous monitoring VE Johnson, JD Cook Clinical Trials 6 (3), 217-226, 2009 | 52 | 2009 |
| Accounting for patient heterogeneity in phase II clinical trials JK Wathen, PF Thall, JD Cook, EH Estey Statistics in medicine 27 (15), 2802-2815, 2008 | 49 | 2008 |
| A case for robust Bayesian priors with applications to clinical trials JD Cook, JA Fúquene, LR Pericchi | 48 | 2009 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 47 | 2022 |
| The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty: part 1: the development of an evidence-based model linking preoperative score to … AJ Price, S Kang, JA Cook, H Dakin, A Blom, N Arden, R Fitzpatrick, ... The Bone & Joint Journal 102 (7), 941-949, 2020 | 45 | 2020 |
| Basic properties of the soft maximum JD Cook bepress, 2011 | 45 | 2011 |
| Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation Y Li, BN Bekele, Y Ji, JD Cook Statistics in medicine 27 (24), 4895-4913, 2008 | 41 | 2008 |
| Determining distribution parameters from quantiles JD Cook bepress, 2010 | 32 | 2010 |
| Notes on the negative binomial distribution JD Cook Unknow, October 28, 2009, 2009 | 31 | 2009 |
| Exact calculation of beta inequalities J Cook Houston: University of Texas, MD Anderson Cancer Center, 1-8, 2005 | 30 | 2005 |
| Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children HT Whelan, JD Cook, CM Amlie-Lefond, CA Hovinga, AK Chan, ... Stroke 39 (9), 2627-2636, 2008 | 26 | 2008 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 23 | 2023 |
LUIS PERICCHIProfessor of Mathematics, University of Puerto Rico, Rio Piedras Piedras在 upr.edu 的电子邮件经过验证
